Information Provided By:
Fly News Breaks for December 27, 2019
Dec 27, 2019 | 07:49 EDT
Needham analyst Serge Belanger keeps his Buy rating and $36 price target on Flexion after the release of a "long-anticipated" Zilretta label expansion by the FDA. The analyst believes that the exclusion of "confusing language" from the label helps the company achieve its key goal of removing a "Limitation of Use" component for the drug positioning Flexion to better promote Zilretta usage. Belanger points to the company's unveiling of the 2020 Zilretta sales guidance expected in early January as the next potential catalyst for the stock.
News For FLXN From the Last 2 Days
There are no results for your query FLXN